文献速递心力衰竭与心肌病

射血分数保留的心力衰竭:争议、挑战与未来方向

Heart failure with preserved ejection fraction: controversies, challenges and future directions.
PubMed 文献 · Heart · 2018-01-05

该综述指出射血分数保留的心力衰竭(HFpEF)约占心衰总体负担的近一半,因患者常为老年人且存在多种模拟病及血浆利钠肽正常的新亚群,准确诊断具有挑战性。目前缺乏有效治疗,随机临床试验的中性结果提示对该综合征认识不足;一氧化氮-环磷酸鸟苷-蛋白激酶G信号失调可能是由合并症和衰老驱动的基本异常。文章总结了当前概念与争议,并讨论了新治疗及疾病管理策略。

要点

  • HFpEF约占心衰总体负担近一半,缺乏有效治疗,是重大未满足临床需求。
  • 诊断挑战包括多种HFpEF模拟病及血浆利钠肽浓度正常的HFpEF亚群。
  • 合并症和衰老驱动的一氧化氮-cGMP-PKG信号失调可能是HFpEF基本异常。

核心结论

  • HFpEF异质性强,随机临床试验中性结果提示对该综合征认识不充分,需进一步研究。

研究设计与样本

  • 综述,总结HFpEF当前概念、争议及诊断治疗挑战。

主要发现

  • HFpEF约占心衰总体负担近一半,患者常为老年人且合并多种心脏和非心脏异常。
  • 存在多种HFpEF模拟病及血浆利钠肽浓度正常的HFpEF新亚群。
  • 随机临床试验结果为中性,提示对HFpEF综合征认识不全面。
  • 合并症和衰老驱动的一氧化氮-cGMP-PKG信号失调可能是HFpEF基本异常,导致全身炎症状态和微血管内皮功能障碍。
  • 新型信息学平台正基于统计聚类的临床和生物学特征将HFpEF分为亚表型,能否导向更靶向治疗尚待观察。

临床怎么用

  • 临床诊断HFpEF需注意排除模拟病,并识别血浆利钠肽正常的亚群。
  • 关注合并症和衰老相关的一氧化氮-cGMP-PKG信号失调作为潜在病理机制。
  • 目前缺乏有效治疗,需探索基于亚表型的靶向治疗策略。

局限性

  • HFpEF病因和病理生理存在争议,随机临床试验中性结果反映认识不足。
  • 基于统计聚类的亚表型分类能否导向更靶向治疗尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure with preserved ejection fraction (HFpEF) comprises almost half of the population burden of HF. Because HFpEF likely includes a range of cardiac and non-cardiac abnormalities, typically in elderly patients, obtaining an accurate diagnosis may be challenging, not least due to the existence of multiple HFpEF mimics and a newly identified subset of patients with HFpEF and normal plasma natriuretic peptide concentrations. The lack of effective treatment for these patients represents a major unmet clinical need. Heterogeneity within the patient population has triggered debate over the aetiology and pathophysiology of HFpEF, and the neutrality of randomised clinical trials suggests that we do not fully understand the syndrome(s). Dysregulated nitric oxide-cyclic guanosine monophosphate-protein kinase G signalling, driven by comorbidities and ageing, may be the fundamental abnormality in HFpEF, resulting in a systemic inflammatory state and microvascular endothelial dysfunction. Novel informatics platforms are also being used to classify HFpEF into subphenotypes, based on statistically clustered clinical and biological characteristics: whether such subclassification will lead to more targeted therapies remains to be seen. In this review, we summarise current concepts and controversies, and highlight the diagnostic and therapeutic challenges in clinical practice. Novel treatments and disease management strategies are discussed, and the large gaps in our knowledge identified.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart. 2018. PMID: 29305560. doi:10.1136/heartjnl-2016-310790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。